Literature DB >> 21512133

The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.

Mei Yee Koh1, Robert Lemos, Xiuping Liu, Garth Powis.   

Abstract

Most solid tumors and their metastases experience periods of low oxygen or hypoxia, which is of major clinical significance as it promotes both tumor progression and resistance to therapy. Critical mediators of the hypoxic response are the hypoxia-inducible factors HIF-1α and HIF-2α. The HIFs are nonredundant and regulate both overlapping and unique downstream target genes. Here, we describe a novel mechanism for the switch between HIF-1α- and HIF-2α-dependent transcription during tumor hypoxia caused by the hypoxia associated factor (HAF). HAF is overexpressed in a variety of tumors and its levels are decreased during acute hypoxia, but increased following prolonged hypoxia. We have previously identified HAF as an E3 ubiquitin ligase that binds and ubiquitinates HIF-1α by an oxygen and pVHL-independent mechanism, thus targeting HIF-1α for proteasomal degradation. Here, we show that HAF also binds to HIF-2α, but at a different site than HIF-1α, and increases HIF-2α transactivation without causing its degradation. HAF, thus, switches the hypoxic response of the cancer cell from HIF-1α-dependent to HIF-2α-dependent transcription and activates genes involved in invasion such as MMP9, PAI-1, and the stem cell factor OCT-3/4. The switch to HIF-2α-dependent gene expression caused by HAF also promotes an enriched tumor stem cell population, resulting in highly aggressive tumors in vivo. Thus, HAF, by causing a switch from a HIF-1α- to HIF-2α-dependent response to hypoxia, provides a mechanism for more aggressive growth of tumors under prolonged hypoxia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512133      PMCID: PMC3268651          DOI: 10.1158/0008-5472.CAN-10-4142

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

Review 1.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

2.  HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.

Authors:  William Y Kim; Samanthi Perera; Bing Zhou; Julian Carretero; Jen Jen Yeh; Samuel A Heathcote; Autumn L Jackson; Petros Nikolinakos; Beatriz Ospina; George Naumov; Kathleyn A Brandstetter; Victor J Weigman; Sara Zaghlul; D Neil Hayes; Robert F Padera; John V Heymach; Andrew L Kung; Norman E Sharpless; William G Kaelin; Kwok-Kin Wong
Journal:  J Clin Invest       Date:  2009-08       Impact factor: 14.808

3.  The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.

Authors:  John M Heddleston; Zhizhong Li; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell Cycle       Date:  2009-10-03       Impact factor: 4.534

4.  Human cancers converge at the HIF-2alpha oncogenic axis.

Authors:  Aleksandra Franovic; Chet E Holterman; Josianne Payette; Stephen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-02       Impact factor: 11.205

5.  Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but Not HIF-2alpha.

Authors:  Weibo Luo; Jun Zhong; Ryan Chang; Hongxia Hu; Akhilesh Pandey; Gregg L Semenza
Journal:  J Biol Chem       Date:  2009-11-23       Impact factor: 5.157

6.  HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses.

Authors:  Jessica A Bertout; Amar J Majmundar; John D Gordan; Jennifer C Lam; Dara Ditsworth; Brian Keith; Eric J Brown; Katherine L Nathanson; M Celeste Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

7.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

8.  Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation.

Authors:  Mei Yee Koh; Bryant G Darnay; Garth Powis
Journal:  Mol Cell Biol       Date:  2008-10-06       Impact factor: 4.272

9.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

Review 10.  HIF-1alpha and cancer therapy.

Authors:  Mei Yee Koh; Taly R Spivak-Kroizman; Garth Powis
Journal:  Recent Results Cancer Res       Date:  2010
View more
  134 in total

Review 1.  Hypoxic tumor microenvironment: Implications for cancer therapy.

Authors:  Sukanya Roy; Subhashree Kumaravel; Ankith Sharma; Camille L Duran; Kayla J Bayless; Sanjukta Chakraborty
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-27

2.  A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential.

Authors:  Chung-Gi Lee; Bikul Das; Tara L Lin; Chelsea Grimes; Xin Zhang; Tracey Lavezzi; Li Huang; John Cole; Lillian Yau; Li Li
Journal:  Br J Haematol       Date:  2012-04-18       Impact factor: 6.998

3.  Understanding and targeting resistance to anti-angiogenic therapies.

Authors:  Jeffrey M Clarke; Herbert I Hurwitz
Journal:  J Gastrointest Oncol       Date:  2013-09

Review 4.  Crosstalk between calcium and reactive oxygen species signaling in cancer.

Authors:  Nadine Hempel; Mohamed Trebak
Journal:  Cell Calcium       Date:  2017-01-18       Impact factor: 6.817

5.  Hypoxia: HIF switch.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

Review 6.  New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.

Authors:  David Taïeb; Karel Pacak
Journal:  Trends Endocrinol Metab       Date:  2017-08-31       Impact factor: 12.015

7.  Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

Authors:  Á Ordóñez-Navadijo; E Fuertes-Yebra; B Acosta-Iborra; E Balsa; A Elorza; J Aragonés; M O Landazuri
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Hypoxia-Inducible Factor α Subunits Regulate Tie2-Expressing Macrophages That Influence Tumor Oxygen and Perfusion in Murine Breast Cancer.

Authors:  Kayla J Steinberger; Mary A Forget; Andrey A Bobko; Nicole E Mihalik; Marieta Gencheva; Julie M Roda; Sara L Cole; Xiaokui Mo; E Hannah Hoblitzell; Randall Evans; Amy C Gross; Leni Moldovan; Clay B Marsh; Valery V Khramstov; Timothy D Eubank
Journal:  J Immunol       Date:  2020-09-16       Impact factor: 5.422

9.  Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.

Authors:  Yangsook Song Green; Timothy Sargis; Ethan Conrad Reichert; Eleanor Rudasi; Daniel Fuja; Eric Jonasch; Mei Yee Koh
Journal:  Mol Cancer Res       Date:  2019-01-31       Impact factor: 5.852

10.  5-Benzylglycinyl-amiloride kills proliferating and nonproliferating malignant glioma cells through caspase-independent necroptosis mediated by apoptosis-inducing factor.

Authors:  Nagarekha Pasupuleti; Leonardo Leon; Kermit L Carraway; Fredric Gorin
Journal:  J Pharmacol Exp Ther       Date:  2012-12-14       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.